Eli Eyal

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes

Olivier Rascol, Cheryl Fitzer‐Attas, Robert A. Hauser et al. · The Lancet Neurology · 2011 · 211 citations

Additional Therapies, Parkinson Disease, Clinical Neurology +7

A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics

C. Warren Olanow, Robert A. Hauser, Joseph Jankovic et al. · Movement Disorders · 2008 · 166 citations

Combined Rasagiline and Antidepressant Use in Parkinson Disease in the ADAGIO Study

Kara M. Smith, Eli Eyal, Daniel Weintraub · JAMA Neurology · 2014 · 104 citations

Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study

Ralf Reilmann, Andrew McGarry, Igor D. Grachev et al. · The Lancet Neurology · 2018 · 104 citations

Neurodegenerative Diseases, Medicine, Psychotropic Medication +6

Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial

Werner Poewe, Klaus Seppi, Cheryl Fitzer‐Attas et al. · The Lancet Neurology · 2014 · 95 citations

Parkinsonian Variant, Parkinson Disease, Multiple System Atrophy +5